Candel Therapeutics, Inc. (CADL)
Automate Your Wheel Strategy on CADL
With Tiblio's Option Bot, you can configure your own wheel strategy including CADL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CADL
- Rev/Share 0.0194
- Book/Share 1.752
- PB 3.2135
- Debt/Equity 0.0925
- CurrentRatio 7.041
- ROIC -0.3674
- MktCap 309088227.0
- FreeCF/Share -0.5813
- PFCF -10.3267
- PE -13.0958
- Debt/Assets 0.0787
- DivYield 0
- ROE -0.41
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CADL | BofA Securities | Buy | Neutral | -- | $7 | Sept. 3, 2025 |
| Resumed | CADL | H.C. Wainwright | -- | Buy | -- | $23 | June 30, 2025 |
| Initiation | CADL | Citigroup | -- | Buy | -- | $25 | Feb. 20, 2025 |
| Initiation | CADL | Canaccord Genuity | -- | Buy | -- | $20 | Feb. 19, 2025 |
| Initiation | CADL | BofA Securities | -- | Buy | -- | $15 | Feb. 7, 2025 |
News
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection, in patients with borderline resectable PDAC.
Read More
About Candel Therapeutics, Inc. (CADL)
- IPO Date 2021-07-27
- Website https://www.candeltx.com
- Industry Biotechnology
- CEO Paul-Peter Tak FOCIS,
- Employees 38